{"id":"W2166003630","doi":"10.1634/theoncologist.11-6-624","title":"End Points for Adjuvant Therapy Trials: Has the Time Come to Accept Disease-Free Survival as a Surrogate End Point for Overall Survival?","year":2006,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Surrogate endpoint; Clinical endpoint; Clinical trial; Adjuvant therapy; Adjuvant; End point; Endpoint Determination; Intensive care medicine; Disease; Oncology; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002930352,0.000378865,0.001106156,0.00005368756,0.0006656713,0.0001131887,0.0004751278,0.00008090751,0.0005821984],"category_scores_gemma":[0.001770756,0.0001762277,0.0005735584,0.0001480144,0.000412523,0.00005658965,0.0001917324,0.0001346884,0.00005707758],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000392902,"about_ca_system_score_gemma":0.0003232251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001859483,"about_ca_topic_score_gemma":0.002399992,"domain_scores_codex":[0.9975393,0.0003917347,0.000584679,0.0004565049,0.0004563993,0.0005713783],"domain_scores_gemma":[0.9939939,0.004603472,0.0002559286,0.0007732973,0.0002145238,0.0001588633],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1976151,0.006333627,0.01524649,0.0002876023,0.005640294,0.0002375141,0.004510235,0.0002149598,0.004355017,0.02568391,0.5747033,0.165172],"study_design_scores_gemma":[0.03898536,0.01040392,0.2542437,0.0001033783,0.001447997,0.00001941501,0.000932583,0.000231271,0.001073525,0.03767898,0.654183,0.0006968791],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6317188,0.006751855,0.0005295354,0.3128715,0.002580151,0.01901337,0.003154153,0.0003316858,0.02304899],"genre_scores_gemma":[0.9800367,0.0003067171,0.0003468482,0.003587593,0.001470872,0.002451237,0.0002011146,0.00007276249,0.01152613],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3483179,"threshold_uncertainty_score":0.7186358,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1089362530739013,"score_gpt":0.3720933818658209,"score_spread":0.2631571287919195,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}